**A Review on Risk Factors, Staging and Survival Rates of Endometrial Cancer in Both Black and White Women in Infertility Patients in USA**

V.C.Randeep Raj1, Jogi Prameela2, Bolem Omkar2, Gujju Emmanuel2, Sanaboina Akhila2.

1Head Operations, Clinisol Research PVT Limited, Vishakapatnam.
2Pharm D 4 year, Avanthi Institute of Pharmaceutical Sciences, Cherugupally (v), bhogapuram (m), tagarapuvalsa, Vizianagaram district, Andhra Pradesh.

**ABSTRACT**

This article is focused mainly on risk factors, staging and survival rates of endometrial cancer in infertility patients in both black and white women in United States. These risk factors split in to two groups such as exogenous & endogenous. Exogenous mainly (fertility treatment clomiphene, tamoxifen, human chorionic gonadotropins, human menopausal Gonadotropins & Birth control pills, intra uterine devices) These factors which increases the concentrations of unopposed estrogen for a short periods of time but successful leads to fertility, long-term leads to endometrial cancer, and endogenous risk factors includes mainly (Poly cystic ovary syndrome, Obesity, Diabetes, and Hypertension) these risk factors in infertility women may lead to increased unopposed estrogen in the body may leads to development of endometrial cancer over a period of time. It is the commonest reproductive cancer. Our objective was to assess association between exogenous and endogenous risk factors, in infertility patients staging and survival rates in infertility patients which leads to an endometrial cancer. It is estimated that by 2030, endometrial cancer will become the 6th most common cancer overall, and the 3rd most common among women. In addition, five year survival after an EC diagnosis is lower for black women when compared to white women at every stage of diagnosis. “Early detection leads to early prevention”.

**Key words:**

- Endometrial cancer
- Infertility patients
- Endogenous risk
- Exogenous risk
- Factors
- Staging
- Survival rates

**INTRODUCTION**

In united states every year estimated cancer cases were 1,735,350, and estimated cancer deaths were 609,640 out of that Endometrial estimated cases were more than 63,230 and estimated deaths are 11,350. Endometrial cancer is the most commonest cancer in women. Data from the Surveillance, Epidemiology and End Results program report the age-adjusted incidence rate of EC is lower among black women than white women (24.8 and 26.3 cases per 100,000 women, respectively). Infertility is a most common woman health problem currently affecting up to 10% of reproductive age groups in United States. How infertility is going to be a leading cause to endometrial cancer and differentiate between black and white women. Black women are significantly different with regard to socioeconomic position and marital status. They have a higher prevalence of some risk factors for infertility such as uterine fibroids and excess weight. Out of 100 people only 5% people are diagnosed under the age of 40 years, and over 70% of people are nulliparous at diagnosis. An even larger proportion of premenopausal women are diagnosed with complex atypical hyperplasia, a known precursor of endometrial carcinoma.

Overall, this evidence suggests that there are major differences between black women and white women seeking care for infertility. However, whether these differences are present and contribute to increased infertility in black women in the general population is unknown. Endometrium is the inner layer of uterus it is highly vascularized. The Endometrium is divided in two layers, the stratum functionalis lines the uterine cavity and sloughs off during menstruation. The deeper layer the stratum basalis is permanent and gives rise to new stratum functionalis after each menstruation. Thus, exploring factors associated with EC may provide insight regarding racial differences that potentially impact incidence and ultimately survival. Black women have a higher proportion of non-endometrioid tumors, such as serous or clear cell cancers, which may be less hormonally-dependent. The aim of this study was to compare the risk factors for endometrial cancer in black and white women in infertility patients. After a woman is diagnosed with endometrial cancer, doctors will describe staging. Staging describes the amount of cancer in the body. The 5-year survival rate is the percentage of people who live at least 5 years after being diagnosed with cancer.
### METHODS

The analysis was done according to PRISMA guidelines. A literature search was performed using Medline, Embase, and the Cochrane Library and Google Scholar databases for comparative studies until 2017 to investigate a clinical significance of risk factors of endometrial cancer in infertility patients. The following search headings were used: fertility agents, infertility, female, endometrial cancer, neoplasms, clomiphene, tamoxifen, hCG, hMG, intrauterine devices, birth control pills, diabetes, PCOS, obesity, hypertension. Using these strategies, the study was comparing endogenous risk factors and exogenous risk factors causing an endometrial cancer in infertility patients in both black and white women.

### POLY CYSTIC OVARY SYNDROME

PCOS on long term risk mainly associated with endometrial cancer. PCOS leads to an ovulation which characterizes the syndrome is considered to be the main mechanism responsible for continual unopposed secretion of estrogen’s where estrogen receptors are present on endometrium and consequent increase in growth stimulating factor which leads to progressive changes from benign proliferation to atypical hyperplasia which leads to adenocarcinoma risk of an endometrial carcinoma. Endometrial hyperplasia may be a precursor to adenocarcinoma. In women with PCOS, intervals between menstruations of more than three months may be associated with endometrial hyperplasia and later carcinoma.

### OBESITY

Healthy weight BMI is 18.5-24.9, overweight BMI IS >25, obese is >30. Obesity people are more risk for causing an endometrial cancer in both black and white women. Adipose tissue is the primary site for the conversion of adrenal androstenedione to oestrone, which in turn leads to low levels of sex hormone binding globulins which leads to greater bioavailability of estrogen, which leads to progressive changes from endometrial hyperplasia to endometrial carcinoma.

| STAGE | STAGE GROUPING | FIGO STAGE | STAGE DESCRIPTION |
|-------|----------------|------------|-------------------|
| I     | T1 N0 M0       | I          | The cancer is growing within the body of the uterus. It may grow in to the glands of the cervix (T1). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IA    | T1a N0 M0      | IA         | The cancer is in the endometrium and spread to the myometrium (T1a). No spread to nearby lymph node. No Metastasis. |
| IB    | T1b N0 M0      | IB         | Cancer spreads from endometrium to myometrium. But it doesn’t spread to body of uterus (T1b). No spread to nearby lymph node (N0). No Metastasis (M0). |
| II    | T2 N0 M0       | II         | The cancer spreads outside of the uterus (T2). No spread to nearby lymph node (N0). No Metastasis (M0). |
| III   | T3 N0 M0       | III        | Cancer spread to outside of the uterus (T3). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IIIA  | T3a N0 M0      | IIIA       | Cancer spreads to the outer surface of uterus and also spreads to the fallopian tubes (T3a). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IIIB  | T3b N0 M0      | IIIB       | Cancer spreads to the vagina or parametrium (T3b). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IIIC1 | T1-T3 N1,N1mi or N1a M0 | IIIC1 | Cancer growing to the body of uterus, spreads to the nearby tissues (T1-T3). Spread to pelvic lymph node (N1 or N1mi or N1a). No Metastasis (M0). |
| IIIC2 | T1-T3 N2,N2mi or N2a M0 | IIIC2 | Cancer spreads to the body of uterus, spreads to nearby tissues (T1-T3). Spread to pelvic lymph node (N2 or N2mi or N2a). No Metastasis (M0). |

| M0    | T3.         |          | spreads to para aortic lymph nodes (N2 or N2a) No Metastasis (M0). |
| IV    | T4 ANY N M0 | IV        | Cancer spreads to the inner lining of rectum and urinary bladder (T4). It may or may not spread to the nearby lymph node (ANY N). No Metastasis (M0). |
| IVB   | ANY T ANY N M1 | IVB   | The cancer be any size (ANY T) it may or may not be to nearby lymph node (ANY N). It spreads to groin lymph node, it spreads to organs away from uterus to other organs such as liver, lung, or bones (M1). |

---

**Staging:**

| STAGE | STAGE GROUPING | FIGO STAGE | STAGE DESCRIPTION |
|-------|----------------|------------|-------------------|
| I     | T1 N0 M0       | I          | The cancer is growing within the body of the uterus. It may grow in to the glands of the cervix (T1). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IA    | T1a N0 M0      | IA         | The cancer is in the endometrium and spread to the myometrium (T1a). No spread to nearby lymph node. No Metastasis. |
| IB    | T1b N0 M0      | IB         | Cancer spreads from endometrium to myometrium. But it doesn’t spread to body of uterus (T1b). No spread to nearby lymph node (N0). No Metastasis (M0). |
| II    | T2 N0 M0       | II         | The cancer spreads outside of the uterus (T2). No spread to nearby lymph node (N0). No Metastasis (M0). |
| III   | T3 N0 M0       | III        | Cancer spread to outside of the uterus (T3). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IIIA  | T3a N0 M0      | IIIA       | Cancer spreads to the outer surface of uterus and also spreads to the fallopian tubes (T3a). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IIIB  | T3b N0 M0      | IIIB       | Cancer spreads to the vagina or parametrium (T3b). No spread to nearby lymph node (N0). No Metastasis (M0). |
| IIIC1 | T1-T3 N1,N1mi or N1a M0 | IIIC1 | Cancer growing to the body of uterus, spreads to the nearby tissues (T1-T3). Spread to pelvic lymph node (N1 or N1mi or N1a). No Metastasis (M0). |
| IIIC2 | T1-T3 N2,N2mi or N2a M0 | IIIC2 | Cancer spreads to the body of uterus, spreads to nearby tissues (T1-T3). Spread to pelvic lymph node (N2 or N2mi or N2a). No Metastasis (M0). |

| M0    | T3.         |          | spreads to para aortic lymph nodes (N2, N2a). No Metastasis (M0). |
| IV    | T4 ANY N M0 | IV        | Cancer spreads to the inner lining of rectum and urinary bladder (T4). It may or may not spread to the nearby lymph node (ANY N). No Metastasis (M0). |
| IVB   | ANY T ANY N M1 | IVB   | The cancer be any size (ANY T) it may or may not be to nearby lymph node (ANY N). It spreads to groin lymph node, it spreads to organs away from uterus to other organs such as liver, lung, or bones (M1). |
DIABETES
Independent of obesity, the presence of a defect in insulin action which amplifies LH stimulated androgen secretion from theca cells, has been well established. Insulin binding sites are present in endometrium which stimulates insulin and insulin like growth factors are raised in PCOS. Hyperandrogenism and hyperinsulinemia may increase the potential for neoplastic change in the endometrium. It is reported that more than 20% of obese women with PCOS will have impaired glucose tolerance after the age of 30. Evidence demonstrates that the prevalence of type 2 diabetes in women diagnosed with PCOS is 7 times higher than controls. Insulin resistance combined with abdominal obesity is thought to account for the higher prevalence of type 2 diabetes in PCOS. However, the risk of developing type 2 diabetes is also increased in non-obese women with PCOS. Thus PCOS is an independent risk factor for type 2 diabetes in middle age. The majority of women under 45 with type 2 diabetes are also diagnosed with PCOS. Diabetes causes more risk of endometrial cancer in black women when compared to white.

CARDIOVASCULAR DISEASE AND HYPERTENSION
There are two mechanisms by which insulin resistance in PCOS contributes significantly to higher incidence of cardiovascular disease in these women. One mechanism is the direct atherogenic action and the other mechanism is the adverse effect of the lipoprotein profile. Women with PCOS are seen to have more extensive coronary artery disease by angiography. Impaired glucose tolerance and diabetes caused by PCOS are known risk factors for cardiovascular disease. The lipoprotein profile in women with polycystic ovaries is significantly distorted. They usually have high concentrations of serum triglycerides and total and low-density lipoprotein cholesterol. On the other hand the levels of high density lipoprotein (HDL) and particularly HDL2 subfraction are suppressed. In addition serum plasminogen activator inhibitor-I concentrations are also elevated. The last could lead to impaired fibrinolysis and thus affect directly vascular tissue causing changes associated with coronary heart disease. The evidence is thus mounting that there is indeed an increased risk for women with PCOS of developing cardiovascular disease.

Regarding hypertension there to be a direct relationship between insulin plasma levels and blood pressure. The prevalence of treated hypertension is three times higher in women with PCOS between the ages of 40-59 years in comparison with controls. The incidence of preeclampsia in obese women with PCOS conceiving compared to the general pregnant population is 4 times higher. It seems that significant risk factors for developing atherosclerotic conditions, hypertension and myocardial infarction, are present at an earlier age than women without PCOS.

CLOMIPHENE CITRATE (CC)
The incidence of endometrial cancer after intake of this drugs in United States was estimated as 0.44% (13 of 2974) in the CC. Data was collected from end result and surveillance program.

TAMOXIFENE
Tamoxifen causes estimated chances of getting of endometrial cancer. Any abnormal vaginal bleeding, discharge, staining or spotting should be investigated. Clomiphene citrate and human menopausal gonadotropins (CC + hMG)

The incidence of endometrial cancer was 0.20% (14 of 7023) in the CC + hMG group. Human menopausal gonadotropin (hMG). The incidence of endometrial cancer was 0.07% (5 of 6861) in the hMG.

Birth control pills:
These pills on long-term use may increase estrogen level in the body which may leads to progressive changes from atypical hyperplasia to carcinoma. Only 5% of people are more chance of getting endometrial cancer people who are using contraceptive pills. These are very less chance of causing an endometrial cancer.

Inclusion criteria and exclusion criteria:
All comparative studies of exogenous and endogenous risk factors in infertility patients in black and white women patient groups reporting incidence rates and prevalence rates of endometrial cancer outcomes are included. The term 'fertility treatment' refers here specifically to patients who were administered fertility drugs to induce multiple folliculogenesis, also known as superovulation. Those studies not reporting endometrial cancer incidence either at all or separately in both the exogenous and endogenous risk factors were excluded. Other reproductive tract cancers including the cervix were excluded from our analysis.

RESULTS
Based on various studies we have concluded that white women have a higher incidence of endometrial cancer than black women their mortality is higher, based on ethnicity and race estimated percentage of occurring endometrial cancer up to 2017 is blacks 24.8% and whites is 26.3 %. Overall incidence rates are 25.6% and overall estimated death rates are 4.6%. But in black women estimated death rates are 8.1% and white women death rates are 4.2%. Because black women diagnosed with less favourably histologies and more poorly differentiated tumours when compared to white. PCOS, diabetes, obesity all important risk factors increasing a women probability for endometrial cancer 5-10 times compared with patients without risk factors. There is evidence to support higher incidence in westernized populations. A number of studies have shown that diets high in fat and low in complex carbohydrates and fiber increases a woman risk of endometrial cancer. Large body mass and obesity in particular cases women at increased risk of endometrial cancer. Obese woman have higher endogenous oestrogens than lean women. For each 5kg weight gain the risk for developing endometrial cancer increases by 21%. Prevention of endometrial cancer requires early detection and diagnosis of atypical hyperplasia. The most important predictor of outcome and survival in women with endometrial cancer is tumour stage. Stage I disease is limited to the uterus corpus without involvement of serosa. With 5 years survival rates of 75%. In stage II the uterus is involved and disease extends to the cervix and survival is 69%. In stage III cancer spreads to the body of uterus and survival rates are 47%. In stage IV cancer spreads to regional or distant metastasis and disease has spread the outside of uterus and survival rates are 15%.
DISCUSSION AND CONCLUSION

This review analysis offers the first estimates of risk associated with EC in black women for common risk factors. The prevalence of these risk factors vary by race in the US population. Obesity is the strongest risk factor for EC among all women examined in this study. A potentially modifiable risk factor, obesity is linked with a number of cancers, but the strongest association is with EC. The previously reported relative risk of 1.6 per 5 kg/m² incremental increase is similar to the 3-fold increase among both black and white women we reported between women who were obese and those of normal weight. Overweight women are also at increased risk of EC, although the effect size is more modest. The racial disparity in obesity prevalence between black and white women has been widely reported. With a greater proportion of black women classified as obese, one would expect to see higher incidence of endometrial cancer among black women, as has been reported when the higher prevalence of hysterectomies is accounted for in the black population. Similar to our findings, the association between type II diabetes and EC has been reported in various studies. Reporting an approximate 2-fold increase in risk, Prevalence of type II diabetes continues to rise in the United States, and remains relatively higher among black women. The prevalence of childlessness increased more rapidly among black women than among white women during this time period (30% increase among blacks compared to 11% in whites). pcos is other major risk factor for causing an endometrial cancer majorly predispose in black women compared to white women. Short term fertility treatment leads less risk of endometrial cancer compared to long term treatment. There is less usage of these drugs among black and white women so there is less risk of an endometrial cancer. Oral contraceptives usage is also very less among black so there is less chance of causing an disease conclusion: Risk factors of an endometrial cancer in black and white women in infertility patients. In infertility patients compared to exogenous, endogenous risk factors are major chances of an occurring an endometrial carcinoma especially in black women more chances of causing an endometrial cancer.so” early detection leads to early prevention”.so if we find in an early stages of cancer so we can go with an alternative treatment. In final stage hysterectomy is only option. Finally in endometrial carcinoma death is only option.so preventive measures should be taken. By 2030, endometrial cancer will become the 6th most common cancer overall, and the 3rd most common among women.

Fig 02: percent of new cases by age groups of endometrial cancer

Graphical representation of data

Fig 02: Graphical representation of data

AKNOWLEDGEMENT

To American cancer society and surveillance, epidemiology & end result program.

REFERENCES

1. Gerard J.,tortora,bryan derrickson principles of anatomy and physiology 13th edition ,volume 2 ,pg no 1151-1153.
2. American Joint Committee on Cancer. Corpus Uteri-Carcinoma and Carcinosarcoma. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017:661-669.
3. Freeman SF et al. The Revised FIGO Staging System for Uterine Malignancies: Implications for MR Imaging, Radiographics. 2012; 32:1805–1827.
4. American Joint Committee on Cancer. Uterine Cancer. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 403-409.
5. Clinical green top guidelines. RCOG. 2007;33.
6. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 2001;98:325–331.
7. Gopal M, Duntley S, Uhles M, Attarain H. The role of obesity in the increased prevalence of obstructive
sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med. 2002;3:401–404.

8. Wild RA. Long term health consequences of PCOS. Hum Reprod Update. 2002;8:231–241.

9. Balen A, Rajkhowa R. Health consequences of polycystic ovary syndrome. In: Balen A, editor. Reproductive endocrinology for the MRCOG and beyond. 1st ed. London: RCOG press; 2003. pp. 99–107.

10. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial cancer. Lancet. 2003;361:1810–1812.

11. Cho LW, Jayagopal V, Kilpatrick ES, Atkin SL. The biological variation of C-reactive protein in polycystic ovarian syndrome.

12. Wijeyaratne CN, Balen AH, Barth J, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol. 2002;57:343–350.

13. Legro RS, Kunselman AR, Dodson WC, Dunai A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169.

14. Pierpont T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at longterm follow-up. J Clin Epidemiol. 1999;51:779–786.

15. Legro RS, Kunselman AR, Dunai A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607–613.

16. Raikowha M, Glass MR, Rutherford AJ, Michelmore K, Balen AH. Polycystic ovary syndrome: a risk factor for cardiovascular disease? Br J Obstet Gynecol. 2000;107:11–18.

17. Legro RS, Kunselman AR, Dunai A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607–613.

18. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and sympathoadrenal system. New Engl J Med. 1996:334–374. [PubMed]

19. Cheang KL, Nestler JE, Futterweit W. Risk of cardiovascular events in mothers with polycystic ovary syndrome. Endocr Pract. 2008;14:1084–1094

20. Joint British Societies’ guidelines. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1–52.

21. Rose PG (1996) Endometrial carcinoma. N Engl J Med. 335: 640–649.

22. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, et al. (2005) Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 105:575-580.

23. Gallup DG, Stock RJ (1984) Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 64: 417-420.